XenoTech Adds In Vitro Toxicology to Its Drug Development Services

Excerpts from http://www.xenotechllc.com/company/news-events/press-releases/xenotech-announces-the-addition-of-in-vitro-toxico.aspx

Contract Research Organization XenoTech, LLC, a division of Sekisui, announces the addition of in vitro toxicology to its global drug development service portfolio. The company is launching the ECVAM validated skin irritation screening assay (OECD TG 439) immediately, with additional screens for skin sensitization, ocular irritation and other organotypic models beginning this fall (2015) and future platforms expanding into endocrine disruption, genetox and hepatotoxicity.

XenoTech has appointed Colleen Toole, Ph.D., as the Principal Scientist of its newly created in vitro toxicology group. Colleen will oversee all operations of the new department and will be instrumental in the continued development of XenoTech’s in vitro toxicology services. Colleen has a strong knowledge of predictive in vitro toxicology models to identify new drug candidates, chemicals, cosmetics, and consumer products that present a low risk for toxicity.

“The formation of our new in vitro toxicology department shows XenoTech’s commitment to expanding into complementing areas around our extensive ADME - DMPK expertise. This natural extension of our capabilities will enable us to better predict in vivo outcomes through in vitro systems,” said XenoTech COO Jason Neat.

XenoTech is combining the thorough investigation of compounds with internal in vitro expertise to design the most robust in vitro systems on the market. The company is focused on delivering both regulated and non-regulated assays that will provide the client with a definitive answer regarding the toxicity of their compound.